Cargando…

An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine

There has been growing interest in reported cases of IgA nephropathy (IgAN) flare-up following administration of the coronavirus disease 2019 (COVID-19) vaccine. Our patient is a previously healthy 17-year-old girl who presented with a 10-year history of microscopic hematuria. Because there were no...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Mari, Kikuchi, Eriko, Nagasawa, Masayuki, Oshiba, Akihiro, Shimoda, Masuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812345/
https://www.ncbi.nlm.nih.gov/pubmed/35118635
http://dx.doi.org/10.1007/s13730-021-00679-7
_version_ 1784644629305491456
author Okada, Mari
Kikuchi, Eriko
Nagasawa, Masayuki
Oshiba, Akihiro
Shimoda, Masuhiro
author_facet Okada, Mari
Kikuchi, Eriko
Nagasawa, Masayuki
Oshiba, Akihiro
Shimoda, Masuhiro
author_sort Okada, Mari
collection PubMed
description There has been growing interest in reported cases of IgA nephropathy (IgAN) flare-up following administration of the coronavirus disease 2019 (COVID-19) vaccine. Our patient is a previously healthy 17-year-old girl who presented with a 10-year history of microscopic hematuria. Because there were no abnormal findings in blood examination or ultrasonography, we followed her up twice per year as asymptomatic hematuria. Although she never developed gross hematuria when she had upper respiratory infections or received an influenza vaccine, she presented with gross hematuria and proteinuria within a few days after receiving the first dose of the Pfizer vaccine. We performed renal biopsy 2 weeks after the first vaccination. It revealed minor glomerular abnormalities with diffuse mesangial IgA deposits, and we diagnosed her with mild IgAN. Gross hematuria was detected after both the first and second doses, although it changed to microscopic hematuria within 1 week. Additionally, her proteinuria resolved spontaneously approximately 10 days after the second dose of the vaccine. Therefore, we opted to observe her without administering medication. The causation between COVID-19 vaccination and IgAN flare-up remains unclear. Several reports showed IgAN patients presenting gross hematuria following the second dose of the Pfizer or Moderna vaccines. However, our patient developed gross hematuria and proteinuria even after the first dose and without known severe acute respiratory syndrome coronavirus 2 exposure. Nephrologists should inform both patients with IgAN and those with asymptomatic hematuria that this side effect can occur even after the first vaccination.
format Online
Article
Text
id pubmed-8812345
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-88123452022-02-04 An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine Okada, Mari Kikuchi, Eriko Nagasawa, Masayuki Oshiba, Akihiro Shimoda, Masuhiro CEN Case Rep Case Report There has been growing interest in reported cases of IgA nephropathy (IgAN) flare-up following administration of the coronavirus disease 2019 (COVID-19) vaccine. Our patient is a previously healthy 17-year-old girl who presented with a 10-year history of microscopic hematuria. Because there were no abnormal findings in blood examination or ultrasonography, we followed her up twice per year as asymptomatic hematuria. Although she never developed gross hematuria when she had upper respiratory infections or received an influenza vaccine, she presented with gross hematuria and proteinuria within a few days after receiving the first dose of the Pfizer vaccine. We performed renal biopsy 2 weeks after the first vaccination. It revealed minor glomerular abnormalities with diffuse mesangial IgA deposits, and we diagnosed her with mild IgAN. Gross hematuria was detected after both the first and second doses, although it changed to microscopic hematuria within 1 week. Additionally, her proteinuria resolved spontaneously approximately 10 days after the second dose of the vaccine. Therefore, we opted to observe her without administering medication. The causation between COVID-19 vaccination and IgAN flare-up remains unclear. Several reports showed IgAN patients presenting gross hematuria following the second dose of the Pfizer or Moderna vaccines. However, our patient developed gross hematuria and proteinuria even after the first dose and without known severe acute respiratory syndrome coronavirus 2 exposure. Nephrologists should inform both patients with IgAN and those with asymptomatic hematuria that this side effect can occur even after the first vaccination. Springer Nature Singapore 2022-02-03 /pmc/articles/PMC8812345/ /pubmed/35118635 http://dx.doi.org/10.1007/s13730-021-00679-7 Text en © Japanese Society of Nephrology 2022
spellingShingle Case Report
Okada, Mari
Kikuchi, Eriko
Nagasawa, Masayuki
Oshiba, Akihiro
Shimoda, Masuhiro
An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
title An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
title_full An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
title_fullStr An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
title_full_unstemmed An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
title_short An adolescent girl diagnosed with IgA nephropathy following the first dose of the COVID-19 vaccine
title_sort adolescent girl diagnosed with iga nephropathy following the first dose of the covid-19 vaccine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812345/
https://www.ncbi.nlm.nih.gov/pubmed/35118635
http://dx.doi.org/10.1007/s13730-021-00679-7
work_keys_str_mv AT okadamari anadolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT kikuchieriko anadolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT nagasawamasayuki anadolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT oshibaakihiro anadolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT shimodamasuhiro anadolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT okadamari adolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT kikuchieriko adolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT nagasawamasayuki adolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT oshibaakihiro adolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine
AT shimodamasuhiro adolescentgirldiagnosedwithiganephropathyfollowingthefirstdoseofthecovid19vaccine